摘要
目的探讨中药肺积方抑制裸鼠移植瘤组织血管生成及促进肿瘤血管正常化的作用及其机制。方法采用人肺腺癌细胞株SPAC-1建立BALB/c裸鼠鼠背视窗模型,造模后将裸鼠随机分为空白组及肺积方高、中、低剂量组。用共聚焦显微镜活体观察各组裸鼠活体背部视窗的肿瘤内部血管,计算瘤内单位面积的平均血管数量和直径;同时用免疫荧光染色法观察肿瘤血管壁Ⅳ型胶原(Collagen-Ⅳ)及血管平滑肌抗体(a-SMA)细胞覆盖率。结果在干预后第5天,高剂量组小鼠瘤径显著小于空白组(P<0.05);第9天,高剂量组与中剂量组血管数明显少于空白组(P<0.05),且高剂量组的血管平均直径明显小于中剂量组(P<0.05);第14天,高剂量组、中剂量组血管数明显少于空白组(P<0.05),且高剂量组瘤径明显小于空白组和低剂量组(P<0.05)。自药物干预第6天始,肿瘤血管a-SMA和Collegen-Ⅳ覆盖率较空白组逐步升高,其中高、中剂量组较空白组升高明显(P<0.05)。结论肺积方具有抑制肿瘤血管生成并可促进肿瘤血管正常化的作用,其机制与增加肿瘤血管aSMA和Collegen-Ⅳ覆盖率相关。
Objective To explore the inhibitory effect of "Feiji Prescription" on tumor angiogenesis in nude mice,and to discuss its mechanism.Methods The rats with SPAC-1 were randomly divided into blank group and "Feiji Prescription" groups(small,medium,large dose).The blood vessels in dorsal chamber were observed by confocal microscopy in vivo to calculate the numbers and diameters;the coverage rate of Collagen-Ⅳ and a-SMA on vascular wall were observed by immunofluorescent staining assay.Results On the 5th day after "Feiji Prescription" intervention,the tumor diameter in the large dose of "Feiji Prescription" group was markedly less than that of the blank group(P0.05);on the 9th day after treatment,the vessel number in large and medium dose groups were significantly lower than that of the control group(P0.05),and the vessel diameter in the large dose group was significantly lower than that of the medium dose group(P0.05);on the 14th day after intervention,the vessel number in the large dose group and medium dose group were significantly lower than that of the control group(P0.05),and the tumor diameter in the high dose group was markedly less than that of the control group and small dose group(P0.05).The Collagen-Ⅳ and a-SMA coverage rate of the vascular tumor was increased from the 6th day after treatment,and the coverage rate in large dose group and medium dose group was significantly higher than that of the blank group(P0.05).Conclusion "Feiji Prescription" can inhibit tumor angiogenesis and normalize tumor vascular.The mechanism may be associated with the improvement of the coverage rates of Collegen-Ⅳ and a-SMA.
出处
《上海中医药杂志》
2013年第6期84-88,共5页
Shanghai Journal of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(30973724)